Diagnosis of Allergic Complaints, Atopic Diseases and/or Auto-Immune Diseases by the Identification of Antibodies Against CD28 in Human Serum

Simple SummaryContent extracted from patent full text and abstract with AI.

This patent describes a novel diagnostic method and kit for the in vitro detection of allergic complaints, atopic diseases, and autoimmune diseases by identifying autoantibodies against CD28 in human serum. By bringing a patient's sample into contact with the CD28 molecule, the method detects whether anti-CD28 autoantibodies are present, which indicates the likelihood of these diseases. The invention includes the use of CD28 (either full length or a relevant fragment) and involves standard laboratory techniques like ELISA or immunoblotting to facilitate the diagnosis.

Use CasesContent extracted from patent full text and abstract with AI.

• Diagnosis of allergic diseases such as allergic rhinitis (hay fever) or allergic asthma in clinical laboratories.
• Diagnosis of atopic diseases including atopic dermatitis (eczema) in both pediatric and adult patients.
• Early identification of autoimmune diseases such as scleroderma, lupus erythematosus, rheumatoid arthritis, or dermatomyositis by detecting anti-CD28 autoantibodies.
• Supplementary diagnostic tool for cases where traditional allergy tests (like total IgE measurement or skin prick tests) yield ambiguous results.
• Assessment of disease severity or risk of progression in patients with known atopic or autoimmune disorders, given that higher autoantibody titers correlate with disease severity.
• Development of test kits for use in hospitals, clinics, or reference labs to streamline the diagnostic process.

BenefitsContent extracted from patent full text and abstract with AI.

• Provides a new, specific biomarker (anti-CD28 autoantibodies) for the diagnosis of a broad spectrum of immune-related disorders.
• Improves accuracy in diagnosing diseases where conventional allergy or autoimmune markers may be non-specific or inconclusive.
• Enables earlier detection and intervention, potentially improving patient outcomes, especially in pediatric or ambiguous clinical cases.
• Can be implemented using standard laboratory equipment and well-established techniques (such as ELISA or immunoblotting), facilitating easy adoption.
• Correlates antibody levels with disease severity, offering potential for disease monitoring and risk assessment.
• Supports combined or multiplexed testing approaches by integrating with current IgE testing or other immunological assays.

Technical Classifications (CPCs)

Inventors & Applicants

Patent Abstract

The invention relates to a method for diagnosing allergic complaints, atopic diseases and/or auto-immune diseases, according to which a sample from a patient is analysed for the presence of anti-CD28 auto-antibodies by bringing said sample into contact with CD28. If auto-antibodies bond to the CD28, this indicates the presence of an allergic complaint, atopic disease and/or auto-immune disease. The invention also relates to the use of CD28 for diagnosing said diseases and to a kit that is designed for this purpose, comprising CD28 and marked anti-immunoglobulin antibodies.